Stem Cell ReportsDevelopmental BiologyPeer-reviewed journal article
Human iPSC-Based Model Reveals NOX4 as Therapeutic Target in Duchenne Cardiomyopathy
Robin DueleniD, Domiziana CostamagnaiD, Guillaume GilbertiD, Liesbeth De WaeleiD, Nathalie GoemansiD, Kaat DesloovereiD, Catherine M. VerfaillieiD, Karin R. SipidoiD, Gunnar BuyseiD, Maurilio SampaolesiiD
Abstract
Duchenne muscular dystrophy (DMD) is an X-linked progressive muscle disorder, caused by mutations in the Dystrophin gene. Cardiomyopathy is one of the major causes of early death. In this study, we used DMD patient-specific induced pluripotent stem cells (iPSCs) to model cardiomyopathic features in DMD and unravel novel pathological mechanistic insights. Cardiomyocytes (CMs) differentiated from DMD iPSCs showed enhanced premature cell death, due to significantly elevated intracellular reactive oxygen species (ROS) concentrations, as a result of depolarized mitochondria and high NADPH oxidase 4 (NOX4) protein levels. Genetic correction of Dystrophin through CRISPR/Cas9 editing restored normal ROS levels. Application of ROS reduction by N-acetyl-L-cysteine (NAC), partial Dystrophin re-expression by ataluren (PTC124) and enhancing mitochondrial electron transport chain function by idebenone improved cell survival of DMD iPSC-CMs. We show applications that could counteract the detrimental oxidative stress environment in DMD iPSC-CMs by stimulating adenosine triphosphate (ATP) production. ATP could bind to the ATP-binding domain in the NOX4 enzyme, and we demonstrate that ATP resulted in partial inhibition of the NADPH-dependent ROS production of NOX4. Considering the complexity and the early cellular stress responses in DMD cardiomyopathy, we propose to target ROS production and prevent the detrimental effects of NOX4 on DMD CMs as a promising therapeutic strategy. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=99 SRC="FIGDIR/small/460090v1_ufig1.gif" ALT="Figure 1"> View larger version (28K): org.highwire.dtl.DTLVardef@d3606borg.highwire.dtl.DTLVardef@15f1d88org.highwire.dtl.DTLVardef@18bfb9corg.highwire.dtl.DTLVardef@133c6bd_HPS_FORMAT_FIGEXP M_FIG The use of human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) from Duchenne muscular dystrophy (DMD) patients to model cardiomyopathic features in DMD and unravel novel pathological mechanistic insights. DMD iPSC-CMs showed accelerated cell death, caused by increased intracellular reactive oxygen species (ROS) levels. By intervention at different target sites, beneficial effects on the mitochondrial membrane potential ({Delta}{Psi}m) and the expression and ROS-producing activity of the cardiac-specific NADPH-oxidase 4 isoform (NOX4) were observed, resulting in an increased cell survival and function of DMD iPSC-CMs. C_FIG
- Citations
- 29
- FWCI
- 1.96
- Field percentile
- top 13%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Gene-corrected human iPSC-derived cardiomyocytes and skeletal muscles reveal partial dystrophin Dp427 preservation and cardiac Dp116 expression in Duchenne muscular dystrophy
Marta Białobrzeska, Marta Przymuszała, … Józef Dulak·medRxiv·Jul 11, 2025
- Reversal of cardiac and skeletal manifestations of Duchenne muscular dystrophy by cardiosphere-derived cells and their exosomes in mdx dystrophic mice and in human Duchenne cardiomyocytes
Mark A. Aminzadeh, Russell G. Rogers, … Eduardo Marbán·bioRxiv·Apr 20, 2017
- NOX4 inhibition promotes the remodeling of dystrophic muscle
D. W. Hammers·bioRxiv·Jan 8, 2022
- Phenotypic Switching of Vascular Smooth Muscle Cells in Duchenne Muscular Dystrophy
- TRF2 rescues telomere attrition and prolongs cell survival in Duchenne muscular dystrophy cardiomyocytes derived from human iPSCs
A. Eguchi, S. I. Torres-Bigio, … H. M. Blau·bioRxiv·Jan 10, 2022
- Impaired S-nitrosylation of Cx43 prevents arrhythmogenicity and myocardial injury upon cardiac stress in Duchenne Muscular Dystrophy
Manuel F. Muñoz, Pablo S. Gaete, … Jorge E. Contreras·Cardiovascular ResearchPeer-reviewed·Aug 7, 2026